MUC16 and cancer: We finally tested MSC-derived TR3 variants for functional activity in MUC16-deficient and MUC16-positive cancer cells in vitro to test our hypothesis that MSC-derived supernatant containing Meso64TR3 has enhanced activity profile against MUC16-positive OVCAR3 cells relative to parental TR3 and Ad5 control.